Bavar­i­an Nordic drops can­cer vac­cine ef­forts to fo­cus on in­fec­tious dis­eases

Bavar­i­an Nordic will no longer work on its im­muno-on­col­o­gy vac­cine pro­gram to in­stead fo­cus on in­fec­tious dis­ease R&D, with the com­pa­ny’s “record” 2023 sales buoyed by its mpox vac­cine Jyn­neos.

The Dan­ish biotech was work­ing on a Phase I can­cer vac­cine, dubbed TAEK-VAC, which tar­gets a tu­mor-as­so­ci­at­ed anti­gen. The as­set was be­ing in­ves­ti­gat­ed in sub­jects with chor­do­ma (tu­mor in the spine or at the base of the skull) or HER2-pos­i­tive breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.